Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.
The Federal Reserve lifted confidence amid economic uncertainty, sparking optimism in the U.S. stock market. Chair Jerome Powell kept interest rate steady at policy meeting and maintained the Fed’s two-rate...
A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.